Isoniazide Cas:54-85-3

We are Isoniazide CAS:54-85-3 manufacturer and supplier in China, Pls send inquiry of to of visit our official website should you have any interests


isonicotinoyl hydrazide
isonicotinic acid hydrazid
4-pyridine-carbonic acid hydrazide
pyridine-4-carboxylic acid hydrazide
4-Pyridinecarboxylic acid, hydrazide
Molecular Formula: C6H7N3O
Molecular weight:137.13900

Appearance and properties: white crystalline powder
Density: 1.244g/cm3
Melting point: 171-173 °C(lit.)
Flash point: >250°C
Refractive index: 1.5502 (18ºC)
Water solubility: 14 g/100 mL (25 ºC)
Stability: Stability Stable, but may be air or light sensitive. Combustible. Incompatible with strong oxidizing agents, chloral, aldehydes, iodine, ferric salts, hypochlorites.
Storage conditions: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Uses: Isoniazid is an antibiotic with anti-tuberculosis effect.

Items of Analysis Standard of Analysis Test Results
Appearance White or almost white crystalline powder Conform
Solubility Freely soluble in water, sparingly soluble in alcohol Conform
Identification A-Melting Point: 170-174℃
B-IR: As per BP
pH 6.0-8.0 7.1
Appearance of solution Solution S is clear and not more intensely colored than reference solution BY7 Conforms to RSBY7
Heavy metals ≤10ppm <10ppm
Hydrazine & Related Substances Any secondary spot: ≤0.2%
Hydrazine spot: ≤0.05%
Loss on drying ≤0.50% 0.12%
Sulphated ash ≤0.1% 0.05%
Assay 99.0%-101.0% 99.7%
Conclusion Conforms to BP2015 standard


Market News:The company was one of many to step into the void for needed generic medicines as chronic shortages crippled access to key drugs, specifically in the early- to mid-stages of the pandemic. That shortage actually led the FDA to thaw its relationship with compounding pharmacies — which was once particularly icy — to ramp up production. N,N-diethyl-2-((9-(ethylthio)-9,10-dihydroanthracene-9-carbonyl)oxy)-N-methylethan-1-aminium iodide manufacturer.A number of drugmakers are also developing inhaled treatments for COVID-19, including Verona Pharma. α-Cyano-m-phenoxybenzyl 7-chloro-α-isopropylbenzofuran-4-acetate supplier.AstraZeneca acquired global rights to anifrolumab through an exclusive license and collaboration agreement with Medarex, Inc. in 2004. Medarex was acquired by Bristol-Myers Squibb in 2009. (S)-cyclohexanecarboxylic acid {1-benzyl-2-[4-(3-methoxy-thiophen-2-yl)-3,6-dihydro-2H-pyridin-1-yl]-ethyl}-amide producer.

Related Products
Product Name
2-Chloro-4-dibenzofuran-4-yl-6-phenyl-[1,3,5]triazine View Details
Bromochloromethane View Details
3-(Trifluoromethoxy)benzaldehyde View Details
L-Valine methyl ester hydrochloride manufacturer 3-[3-(trifluoromethyl)phenyl]propanal manufacturer hexamethyldisilazane manufacturer non-8-enoic acid manufacturer 5-Methoxy-3-indolecarboxylic acid manufacturer